Tebipenem HBr (tebipenem pivoxil hydrobromide)

About Spero Therapeutics

Spero Therapeutics is a Boston-based biotech focused on rare diseases and antibiotic-resistant infections, leveraging a capital-efficient, partnership-driven model. Its defining achievement is the positive Phase 3 readout for tebipenem HBr, an oral carbapenem for complicated urinary tract infections, which could become the first oral drug in its class and offers a paradigm shift from IV to oral treatment. The company's strategy involves in-licensing and developing assets with clear differentiation, targeting areas with scarce therapeutic options. With a lean team and a history of strategic collaborations, Spero is poised to advance its lead candidate toward regulatory submission while exploring its pipeline.

Therapeutic Areas